Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2008

View Archived Issues

Erythropoietin may have antidepressant activity

Iloperidone effective in double-blind schizophrenia trials

Quetiapine treatment assessed in depression, anxiety and alcoholism

Idenix gives update on development of HCV nucleotide prodrugs IDX-184 and IDX-102

Nektar initiates phase II clinical program for PEG-Irinotecan in colorectal cancer

Phase II trial begins for oral PEG-naloxol in opioid-induced bowel dysfunction

Rigel enrolls patients in phase I R-348 trial in immune disorders

Pipex initiates phase II trial of anti-copper Coprexa for Alzheimer's disease

Toyama initiates phase II study for antiinfluenza agent T-705 in Japan

FDA accepts Icagen's IND application for senicapoc for asthma

FDA approves Can-Fite's IND application for phase I study of CF-102 for liver cancer

Pluristem to initiate phase I clinical trials of PLX-PAD for the treatment of limb ischemia

FDA lifts clinical hold on Vion's phase III trial of Cloretazine for acute AML

FDA grants approval to Compellis and Pennington to begin phase I clinical studies of CP-404

FDA grants approval to Chemokine to initiate phase II trial of CTCE-9908 for liver cancer

Emergent BioSolutions reports positive results from phase II clinical study of typhoid vaccine

Vivus initiates DM-230 extension study for patients in the OB-202 study of Qnexa

CTS-21166 reduces plasma amyloid beta in phase I study

Surface Logix's SLx-2101 reduces blood pressure in phase IIa clinical trial

Pharmion and MethylGene initiate phase II clinical trial of MGCD-0103 with Vidaza

BioAlliance Pharma receives marketing authorization for Loramyc in the U.K. and Denmark

Corthera's phase II clinical trial of relaxin in acute heart failure begins

Novel analgesic agents reported in patent literature

New antiinfective agents disclosed in recent patents

Companies claim novel antidiabetic agents in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...